MA53490A - Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire - Google Patents

Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire

Info

Publication number
MA53490A
MA53490A MA053490A MA53490A MA53490A MA 53490 A MA53490 A MA 53490A MA 053490 A MA053490 A MA 053490A MA 53490 A MA53490 A MA 53490A MA 53490 A MA53490 A MA 53490A
Authority
MA
Morocco
Prior art keywords
kallicrein
odema
attack
inhibitors
plasma
Prior art date
Application number
MA053490A
Other languages
English (en)
French (fr)
Inventor
Xinming Hao
Peng Lu
Christina Nurse
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA53490A publication Critical patent/MA53490A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053490A 2018-08-30 2019-08-30 Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire MA53490A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725216P 2018-08-30 2018-08-30
US201962808612P 2019-02-21 2019-02-21

Publications (1)

Publication Number Publication Date
MA53490A true MA53490A (fr) 2022-05-04

Family

ID=67953889

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053490A MA53490A (fr) 2018-08-30 2019-08-30 Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire

Country Status (12)

Country Link
US (2) US20200109214A1 (enExample)
EP (1) EP3843840A1 (enExample)
JP (2) JP7585193B2 (enExample)
KR (1) KR20210053928A (enExample)
CN (1) CN113056304A (enExample)
AU (2) AU2019328324B2 (enExample)
BR (1) BR112021003789A2 (enExample)
CA (1) CA3110689A1 (enExample)
IL (1) IL281063A (enExample)
MA (1) MA53490A (enExample)
MX (1) MX2021002349A (enExample)
WO (1) WO2020047352A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2021002349A (es) * 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
CN115297927A (zh) * 2020-01-13 2022-11-04 武田药品工业株式会社 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
CN111704672B (zh) * 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
IL295414B1 (en) * 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3390825B1 (en) * 2015-12-18 2020-09-02 Graco Minnesota Inc. Bellows installation and retention method
MX2021002349A (es) * 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.

Also Published As

Publication number Publication date
EP3843840A1 (en) 2021-07-07
AU2019328324B2 (en) 2025-06-19
CA3110689A1 (en) 2020-03-05
US20230104754A1 (en) 2023-04-06
JP2021535161A (ja) 2021-12-16
IL281063A (en) 2021-04-29
US20200109214A1 (en) 2020-04-09
WO2020047352A1 (en) 2020-03-05
KR20210053928A (ko) 2021-05-12
MX2021002349A (es) 2021-05-31
JP2024113183A (ja) 2024-08-21
WO2020047352A8 (en) 2020-04-16
AU2025230807A1 (en) 2025-10-02
JP7585193B2 (ja) 2024-11-18
BR112021003789A2 (pt) 2021-05-18
CN113056304A (zh) 2021-06-29
AU2019328324A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MA53490A (fr) Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
IL310291A (en) Compositions and methods for inhibition of ras
EP3768664A4 (en) SHP2 INHIBITORS AND USES THEREOF
EP3870579A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3545647A4 (en) REGULATION OF CONFIDENT BLOCKCHAIN TRANSACTIONS
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
EP3600273A4 (en) CD73 INHIBITORS AND USES THEREOF
EP3612030A4 (en) INDOL-AHR INHIBITOR AND USES THEREOF
EP3455205A4 (en) Peptidomimetics for the treatment of norovirus infection
EP3661691A4 (en) SYSTEM FOR LASER TREATMENT OF A TUBE SURFACE
EP3886843A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3866789A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3710600A4 (en) SYSTEMS AND METHODS FOR PREDICTING THE EFFECTIVENESS OF CANCER THERAPY
EP3541386A4 (en) COMPOSITIONS AND METHODS FOR TREATING OPIOID OVERDOSE
IL259691A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3938369A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3340967A4 (en) POLYNUCLEOTIDE NANOPARTICLES FOR MODULATION OF GENE EXPRESSION AND USES THEREOF
EP3399993A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING DUCHENNE MUSCLE DYSTROPHY
EP3445450A4 (en) METHOD FOR TREATING OR PREVENTING LIVER DISEASES
EP4003335A4 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3313818A4 (en) METHOD FOR THE TREATMENT OF KAPOSI SARCOMY OR KSVH-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS AND USES OF BIOMARKERS
EP3947387A4 (en) PRMT5 INHIBITORS AND USES THEREOF
EP3976009A4 (en) BAX INHIBITORS AND USES THEREOF
EP3846793A4 (en) EIF4E INHIBITORS AND USES THEREOF